Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Cash from Financing Activities of -$6.6 million for Q4 2024, up 61.27% year-on-year from -$4.1 million in Q1 2024, and up 46.11% on a QoQ basis from -$12.2 million in Q3 2024.
Curaleaf Holdings (CURLF) Cash from Financing Activities (2019 - 2024) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Cash from Financing Activities for 6 consecutive years, with -$6.6 million the latest figure, recorded in Q4 2024.
- Quarterly Cash from Financing Activities rose 61.27% year-over-year to -$6.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$54.1 million (up 19.26% YoY) and the FY2025 annual result came in at -$73.5 million, down 35.86% from the prior year.
- Cash from Financing Activities advanced to -$6.6 million in Q4 2024 per CURLF's latest filing, from -$12.2 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for CURLF reached as high as $28.6 billion in Q2 2023 and fell as low as -$28.6 billion in Q1 2023.
- A 5-year average of $27.4 million and a median of $1.7 million in 2020 frame the typical range for Cash from Financing Activities.
- The largest YoY upside for Cash from Financing Activities was 59634.52% in 2023 against a maximum downside of 171254.23% in 2023.
- Year by year, Cash from Financing Activities stood at $3.4 million in 2020, then soared by 2674.62% to $95.2 million in 2021, then tumbled by 59.54% to $38.5 million in 2022, then sank by 144.09% to -$17.0 million in 2023, then surged by 61.27% to -$6.6 million in 2024.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$6.6 million, -$12.2 million, and -$15.7 billion for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.58 Mn |
| Dec 31, 2024 | -6.58 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Jun 30, 2024 | -15.73 Bn |
| Jun 30, 2024 | -15.73 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Mar 31, 2024 | 15.70 Bn |
| Dec 31, 2023 | -16.99 Mn |
| Dec 31, 2023 | -16.99 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 28.59 Bn |
| Jun 30, 2023 | 28.59 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Mar 31, 2023 | -28.65 Bn |
| Dec 31, 2022 | 38.53 Mn |
| Dec 31, 2022 | 38.53 Mn |
| Sep 30, 2022 | -27.89 Mn |
| Sep 30, 2022 | -27.89 Mn |